Key facts
- Notable investors include Economic Development Innovations Singapore, NTUitive.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Peregrine Ophthalmic
- ·The full record, as it builds
Funding rounds
No funding rounds for Peregrine Ophthalmic are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Peregrine Ophthalmic
Developer of a nanomedicine product designed for the medical treatment of glaucoma. The company's product is a sustained-release product of latanoprost and maintains a consistent and clinically significant IOP-lowering effect over several months, enabling ophthalmologists to provide successful medical management of glaucoma and other eye diseases.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2013
- Website
- peregrineophthalmic.com/
- Ownership
- Privately Held (backing)
Peregrine Ophthalmic doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peregrine Ophthalmic shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peregrine Ophthalmic in its N-PORT filings yet. We sweep new filings monthly.